Learn more about us.
Newsletter subscription
Never miss the latest insights, blogs and news
Subscribe to our newsletter and never miss the latest insights, events and blogs.
.png)
Marianna is the Content & Social Media Coordinator at Solvay Brussels School - Lifelong Learning.
Never miss the latest insights, blogs and news. Subscribe to our newsletter.
In the swiftly evolving worlds of Biotech and MedTech, understanding intellectual property (IP) strategy is more than a skill—it's a critical part of your toolkit. This isn't just about protecting ideas; it's about integrating IP into your roadmap for success. Here, De Clercq & Partners step up, guiding participants of the Solvay Lifelong Learning's Advanced Master in Biotech & MedTech Ventures (AMBT) programme through the intricacies of IP management to power growth and innovation.
Their first presentation demystifies the value of owning IP. It delves into how you—as part of the next wave of entrepreneurs in Biotech and MedTech—can thrive by sparking innovation and adeptly manoeuvring through legal challenges. They cover everything from invention disclosures and patent management to aligning your IP strategies with your business ambitions, offering you a comprehensive blueprint for weaving IP wisdom into your future ventures.
The second session brings the abstract into the tangible, with a case study tackling the superbug MRSA. This isn't just science; it's a strategic overview of navigating the patent landscape—unlocking funding, planning for the future, and outmanoeuvring competition. Through this hands-on example, you'll see the tangible impacts of IP decisions, from the intricacies of patent drafting to the importance of freedom-to-operate (FTO) studies.
De Clercq & Partners' involvement has been pivotal, equipping Solvay's AMBT students with the know-how to lead at the crossroads of science and business. They've turned IP strategy from a side note into a cornerstone of innovation and business planning, preparing a new breed of leaders to navigate the complexities of the Biotech and MedTech landscapes.
As you explore Solvay's AMBT programme, you will find De Clercq & Partners is among the many industry pioneers collaborating with us. This partnership is a testament to our commitment to providing you with a learning experience grounded in real-world expertise. Through this collective effort by leading experts, you are prepared for the nuanced challenges of the Biotech and MedTech sectors, empowering you to navigate these fields with confidence and strategic expertise. Stay tuned!
Never miss the latest insights, blogs and news. Subscribe to our newsletter.
Subscribe to our newsletter and never miss the latest insights, events and blogs.
What other people like
Arnaud is Strategy Manager at ENGIE, driving innovation, digitalisation, and energy transition. He brings hands-on expertise in strategy, marketing, product development, and organisational design.
2/06/25
Lorent is Professor of Finance and Financial Accounting at Solvay Brussels School and teaches at several universities in Belgium and France. He holds a PhD in Finance and works as a consultant in corporate finance, insurance regulation, and risk management.
27/05/25
Marc has over 35 years of pharmaceutical industry experience across GSK, ViiV Healthcare, and biotech ventures. Founder of XMF Consulting. Gaëlle is an international MedTech executive with deep expertise in Sales, Marketing, and Business Transformation across major corporations. Senior Director of International Marketing at Pulmonx.
26/05/25